Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Beyond KEYNOTE-564 eligibility: A clinical decision aid to refine selection for adjuvant pembrolizumab in clear cell renal cell carcinoma.

Created on 18 Nov 2026

Authors

Rocco Simone Flammia, Umberto Anceschi, Aldo Brassetti, Alfredo Bove, Eugenio Bologna, Giuseppe Chiacchio, Simone D'Annunzio, Maria Consiglia Ferriero, Salvatore Guaglianone, Leslie Claire Licari, Riccardo Mastroianni, Flavia Proietti, Marco Pula, Gabriele Tuderti, Fabio Calabrò, Pierre I Karakiewicz, Riccardo Campi, Daniele Amparore, Costantino Leonardo, Giuseppe Simone

Published in

Urologic oncology. Nov 17, 2026. Epub Nov 17, 2026.

Abstract

Adjuvant pembrolizumab is a standard of care for patients with high-risk clear cell renal cell carcinoma after nephrectomy. However, the KEYNOTE-564-eligible population is heterogeneous, and better tools are needed to refine individual risk assessment.
To develop and internally validate a simple integer-based prognostic score in a real-world cohort of patients eligible for adjuvant pembrolizumab.
We retrospectively identified KEYNOTE-564-eligible patients from a prospectively maintained institutional database. A multivariable Cox regression model was used to predict 48-month disease-free survival (DFS), and regression tree analysis identified informative cutoffs for the derived score. Model performance was assessed by internal bootstrap validation, calibration, Kaplan-Meier analysis, decision curve analysis (DCA), and competing-risk regression accounting for other-cause mortality.
Overall, 402 patients were included. The final model showed moderate discrimination (optimism-corrected C-index 67.8%) and good calibration (mean absolute error 3.3%). The MAGNIS score assigned points for tumor necrosis, age >75 years, M1NED status, inferior vena cava thrombus, Fuhrman grade, and pT4 and/or pN+ disease. Four risk groups were identified (0-1, 2, 3-5, and ≥6 points), with significantly different DFS outcomes (P < 0.0001). DCA showed a net clinical benefit across threshold probabilities of 30%-50%, with a score ≥3 emerging as the most informative cutoff. The score remained associated with recurrence after accounting for competing mortality.
MAGNIS is a simple, internally validated tool that improves risk stratification among KEYNOTE-564-eligible patients and may support shared decision-making regarding adjuvant therapy. External validation is warranted.

PMID:
43045592
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement